Cited by 700Bone health and osteoporosis researchBone health and treatmentsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Open access

Black, Dennis M, Reid, Ian R, Boonen, Steven, Bucci-Rechtweg, Christina, Cauley, Jane A, Cosman, Felicia, Cummings, Steven R, Hue, Trisha F, Lippuner, Kurt, Lakatos, Peter, Leung, Ping Chung, Man, Zulema, Martinez, Ruvie Lou Maria, Tan, Monique, Ruzycky, Mary Ellen, Su, Guoqin, Eastell, Richard·2012·Journal of Bone and Mineral Research

DOI 10.1002/jbmr.1494PMC PMC3427916

Open this paper in CoChat — free account Open PDF

Abstract

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) was extended to 6 years. In this international, multicenter, double-blind, placebo-controlled extension trial, 1233 postmenopausal women who received ZOL for 3 years in the core study were randomized to 3 additional years of ZOL (Z6, n = 616) or placebo (Z3P3, n = 617). The primary endpoint was femoral neck (FN) BMD percentage change from year 3 to 6 in the intent-to-treat (ITT) population. Secondary endpoints included other BMD sites, fractures, biochemical bone turnover markers, and safety. In years 3 to 6, FN-BMD remained constant in Z6 and dropped slightly in Z3P3 (between-treatment difference = 1.04%; 95% confidence interval 0.4 to 1.7; p = 0.0009) but remained above pretreatment levels. Other BMD sites showed similar differences. Biochemical markers remained constant in Z6 but rose slightly in Z3P3, remaining well below pretreatment levels in both. New morphometric vertebral fractures were lower in the Z6 (n = 14) versus Z3P3 (n = 30) group (odds ratio = 0.51; p = 0.035), whereas other fractures were not different. Significantly more Z6 patients had a transient increase in serum creatinine >0.5 mg/dL (0.65% versus 2.94% in Z3P3). Nonsignificant increases in Z6 of atrial fibrillation serious adverse events (2.0% versus 1.1% in Z3P3; p = 0.26) and stroke (3.1% versus 1.5% in Z3P3; p = 0.06) were seen. Postdose symptoms were similar in both groups. Reports of hypertension were significantly lower in Z6 versus Z3P3 (7.8% versus 15.1%, p < 0.001). Small differences in bone density and markers in those who continued versus those who stopped treatment suggest residual effects, and therefore, after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years. However, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fracture, may benefit by continued treatment. (ClinicalTrials.gov identifier: NCT00145327). © 2012 American Society for Bone and Mineral Research

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/jbmr.1494

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multiple imputation after 18+ years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476908 · Cited by 4,072
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citation
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Multiple Imputation After 18+ Years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.2307/2291635 · Cited by 2,686
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citation
Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citation
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citation
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citation
Risk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,876

Flagged first, then by citations

Show all 40 references

Research works printed but not linked: 2

Black, 2004, A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term EXtension (FLEX), J Bone Miner Res., 19
Cosman, 2011, After 3 years of IV zoledronic acid administration, who is at highest risk for subsequent vertebral fractures and who should remain on treatment?, J Bone Miner Res., 26

Sorted by citations

Items 201–300 of 699

Recent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 42
Self-citation
Safety concerns with the long-term management of osteoporosis
Reginster, J., Pelousse, F., & Bruyère, O. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793669 · Cited by 33
Denosumab for the treatment of osteoporosis
McClung, M. R. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2017.01.002 · Cited by 36
Treating osteoporosis
Gupta, A., & MARCH, L. M. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.028 · Cited by 35
The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment
SEIOMM Working Group, Guañabens, N., Moro-Álvarez, M. J., Casado, E., Blanch‐Rubió, J., Gómez‐Alonso, C., Diaz‐Guerra, G. M., del Pino‐Montes, J., Valero, C., Peris, P., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01919-8 · Cited by 33
Safety of Bisphosphonates
Orozco, C., & Maalouf, N. M. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.09.001 · Cited by 33
Bisphosphonate Drug Holiday: Choosing Appropriate Candidates
Ro, C., & Cooper, O. B. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0129-9 · Cited by 32
Long-term treatment strategies for postmenopausal osteoporosis
Cosman, F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000509 · Cited by 33
Self-citation
Tooth extractions in patients under antiresorptive therapy for osteoporosis: Primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw
Poxleitner, P. J., Steybe, D., Kroneberg, P., Ermer, M. A., Ülker, G. M. Y., Schmelzeisen, R., & Voss, P. J. (2020) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2020.02.006 · Cited by 34
Menopause and Aging
Løbo, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00014-7 · Cited by 33
Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
Marozik, P. M., Alekna, V., Руденко, Э. В., Tamulaitienė, M., Rudenka, A., Mastavičiūtė, A., Samokhovec, V., Černovas, A., Kobets, K., & Mosse, I. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221511 · Cited by 31
Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday
Villa, J. C., Gianakos, A. L., & Lane, J. M. (2015) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-015-9469-1 · Cited by 32
Prevention and treatment of bone fragility in cancer patient
Ottanelli, S. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.116 · Cited by 33
Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment
Tsourdi, E. A., Makras, P., Rachner, T. D., Pοlyzos, S. A., Rauner, M., Mandanas, S., Hofbauer, L. C., & Anastasilakis, A. D. (2018) · Bone · doi:10.1016/j.bone.2018.10.001 · Cited by 29
The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence
Chandran, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000564 · Cited by 34
Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta–analysis
Zhang, J., Wang, R., Zhao, Y.-L., Sun, X., Zhao, H.-X., Tan, L., Chen, D., & Xu, H. (2012) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(12)60118-7 · Cited by 30
Clinical practice guidelines for postmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014)
González-Macı́as, J., del Pino‐Montes, J., Olmos, J. M., & Nogués, X. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2015.08.005 · Cited by 31
The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment
Wang, G., Sui, L., Gai, P. Y., Li, G., Qi, X., & Jiang, X. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.67.bjr-2016-0292.r1 · Cited by 30
Minodronate for the treatment of osteoporosis
Ohishi, T., & Matsuyama, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s149236 · Cited by 32
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis
Fontalis, A., & Eastell, R. (2020) · Bone · doi:10.1016/j.bone.2020.115336 · Cited by 31
Self-citation
Treating osteoporosis: risks and management
Zhu, J., & MARCH, L. M. (2022) · Australian Prescriber · doi:10.18773/austprescr.2022.054 · Cited by 31
Pharmacological, Nutritional, and Rehabilitative Interventions to Improve the Complex Management of Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease: A Narrative Review
Alessandro de, S. I. R. E., Lippi, L., Aprile, V., Calafiore, D., Folli, A., D’Abrosca, F., Moalli, S., Lucchi, M., Ammendolia, A., & Invernizzi, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101626 · Cited by 31
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
Törring, O. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15579189 · Cited by 31
Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment
Ferrari, S., Butler, P. W., Kendler, D. L., Miller, P. D., Roux, C., Wang, A. T., Huang, S., Wagman, R. B., & Lewiecki, E. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00271 · Cited by 30
Follow-up Bone Mineral Density Testing: 2023 Official Positions of the International Society for Clinical Densitometry
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 34
A Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.003 · Cited by 30
Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies
Hanley, D. A., McClung, M. R., Davison, K. S., Dian, L., Harris, S. T., Miller, P. D., Lewiecki, E. M., & Kendler, D. L. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.002 · Cited by 31
Long-term risks of bisphosphonate therapy
Watts, N. B. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003308 · Cited by 29
Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea
Lee, S. H., Gong, H. S., Kim, T., Park, S.-Y., Shin, J., Cho, S. W., & Byun, D. W. (2015) · Journal of Bone Metabolism · doi:10.11005/jbm.2015.22.4.167 · Cited by 29
Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data
Bell, K., Hayen, A. D., Glasziou, P., Irwig, L., Eastell, R., Harrison, S. L., Black, D. M., & Bauer, D. C. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2847 · Cited by 30
Self-citation
Anti‐fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Wiessing, K. R., Bolland, M. J., Bastin, S., & Gamble, G. D. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12901 · Cited by 29
Self-citation
Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort
Misof, B. M., Roschger, P., Gabriel, D., Paschalis, E. P., Eriksen, E. F., Recker, R. R., Gasser, J. A., & Klaus Klaushofer, A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1780 · Cited by 28
Rare adverse effects of bisphosphonate therapy
Ilyas, Z., & Camacho, P. M. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000501 · Cited by 28
Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed
Ferrari, S., Lewiecki, E. M., Butler, P. W., Kendler, D. L., Napoli, N., Huang, S., Crittenden, D. B., Pannacciulli, N., Siris, E. S., & Binkley, N. (2020) · Bone · doi:10.1016/j.bone.2020.115287 · Cited by 29
Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Bar, M., Ott, S. M., Lewiecki, E. M., Sarafoglou, K., Wu, J. Y., Thompson, M., Vaux, J. J., Dean, D. R., Saag, K. G., Hashmi, S. K., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.07.001 · Cited by 30
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies
Miller, P. D., Recker, R. R., Harris, S. T., Silverman, S. L., Felsenberg, D., Reginster, J.-Y. L., Day, B.-M., Barr, C. E., & Masanauskaite, D. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2518-z · Cited by 28
Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis
Tan, W., Sun, J., Zhou, L., Li, Y., & Wu, X. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12429 · Cited by 28
Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)
Dimai, H. P., Muschitz, C., Amrein, K., Bauer, R., Cejka, D., Gasser, R. W., Gruber, R., Haschka, J., Hasenoehrl, T., Kainberger, F. M., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02441-2 · Cited by 28
Advances and Unmet Needs in the Therapeutics of Bone Fragility
Ramchand, S. K., & Seeman, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00505 · Cited by 26
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 27
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice
Adami, G., Rahn, E. J., & Saag, K. G. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19876468 · Cited by 29
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
Everts‐Graber, J., Bonél, H., Lehmann, D., Gahl, B., Häuselmann, H., Studer, U., Ziswiler, H., Reichenbach, S., & Lehmann, T. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06863-y · Cited by 32
Socioeconomic status and risk of osteoporotic fractures and the use of DXA scans: data from the Danish population-based ROSE study
Holmberg, T., Möller, S., Rothmann, M. J., Gram, J., Herman, A. P., Brixen, K., Tolstrup, J. S., Høiberg, M., Bech, M., & Rubin, K. H. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4768-2 · Cited by 26
Egyptian consensus on treat-to-target approach for osteoporosis: a clinical practice guideline from the Egyptian Academy of bone health and metabolic bone diseases
Miedany, Y. M. E., Abu-Zaid, M. H., Gaafary, M. M. E., Naby, M. M. H. E., Fathi, N. A., Saber, H. G., Hassan, W. A., Eissa, M., Mohannad, N., Khaled, H. F., et al. (2021) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-020-00056-9 · Cited by 26
Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial
Grey, A. B., Bolland, M. J., Mihov, B., Wong, S., Horne, A. M., Gamble, G. D., & Reid, I. R. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2009 · Cited by 28
Self-citation
Bisphosphonate drug holidays – when, why and for how long?
Anagnostis, P. G., & Stevenson, J. C. (2015) · Climacteric · doi:10.3109/13697137.2015.1099092 · Cited by 26
Risk factors for imminent fractures: a substudy of the FRISBEE cohort
Iconaru, L., Moreau, M., Baleanu, F., Kinnard, V., Charles, A., Mugisha, A., Surquin, M., Benoit, F., Karmali, R., Paesmans, M., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05772-8 · Cited by 26
New insights into treatment of osteoporosis in postmenopausal women
Geusens, P. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000051 · Cited by 26
Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years
Reid, I. R., Horne, A. M., Mihov, B., Bava, U., Stewart, A., & Gamble, G. D. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00003-2 · Cited by 27
Self-citation
Sequential and Long-term Therapy for Osteoporosis
McClung, M. R. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00909-2 · Cited by 26
Osteoporotic Fractures During Bisphosphonate Drug Holiday
Bindon, B., Adams, W., Balasubramanian, N., Sandhu, J., & Camacho, P. M. (2017) · Endocrine Practice · doi:10.4158/ep171975.or · Cited by 25
Actualisation 2018 des recommandations françaises du traitement de l’ostéoporose post-ménopausique
Briot, K., Roux, C., Thomas, T., Blain, H., Buchon, D., Chapurlat, R. D., Debiais, F., Féron, J.-M., Gauvain, J. B., Guggenbuhl, P., et al. (2018) · Revue du Rhumatisme · doi:10.1016/j.rhum.2018.02.005 · Cited by 27
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group
Bilezikian, J. P., Lin, C. J. F., Brown, J. P., Wang, A. T., Yin, X., Ebeling, P. R., Fahrleitner‐Pammer, A., Franek, E., Gilchrist, N. L., Miller, P. D., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05020-8 · Cited by 25
Denosumab for cancer-related bone loss
Dell’Aquila, E., Armento, G., Iuliani, M., Simonetti, S., D’Onofrio, L., Zeppola, T., Madaudo, C., Russano, M., Citarella, F., Ribelli, G., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1814731 · Cited by 26
The bisphosphonates: risks and benefits of long term use
Hermann, A. P., & Abrahamsen, B. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.02.002 · Cited by 25
Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24‐month Clinical Study
Liang, B., Shi, Z., Wang, B., Wu, P., Kong, L., Yao, J., Li, C., & Shi, X. (2017) · Orthopaedic Surgery · doi:10.1111/os.12307 · Cited by 24
Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council
Mazurov, V. I., Lesnyak, O. M., Belova, K. Y., Ershova, O. B., Zotkin, E. G., Marchenkova, L., Kochish, A. Y., ROZhINSKAYa, L. Y., & Skripnikova, I. A. (2019) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20192201157 · Cited by 28
Efficacy of annual zoledronic acid in initial percutaneous kyphoplasty patients with osteoporotic vertebral compression fractures: a 3-year follow-up study
Lü, K., Yin, Y., Li, C., Jin, Y., & Shan, H.-Q. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05816-z · Cited by 24
Guideline No. 422g: Menopause and Osteoporosis
Khan, A. A., Alrob, H. A., Ali, D. S., Dandurand, K., Wolfman, W., & Fortier, M. P. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2021.09.013 · Cited by 24
Mechanistic and therapeutic insights gained from studying rare skeletal diseases
Tosi, L. L., & Warman, M. L. (2015) · Bone · doi:10.1016/j.bone.2015.03.016 · Cited by 24
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
Kendler, D. L., Chines, A. A., Brandi, M. L., Papapoulos, S. E., Lewiecki, E. M., Jy, R., Torres, M. M., Wang, A., & Bone, H. G. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4687-2 · Cited by 24
Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score–Matched Cohort Study
D’Silva, K. M., CROMER, S. J., Yu, E. W.-Y., Fischer, M. A., & Kim, S. C. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4174 · Cited by 24
Osteoporosis: Spotlight on current approaches to pharmacological treatment
Sindel, D. (2023) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2023.13054 · Cited by 24
Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study
Eastell, R., Boonen, S., Cosman, F., Reid, I. R., Palermo, L., Cummings, S. R., & Black, D. M. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2361 · Cited by 23
Self-citation
Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis
Gatti, D., Viapiana, O., Idolazzi, L., Fracassi, E., Ionescu, C., Dartizio, C., Troplini, S., Kunnathully, V., Adami, S., & Rossini, M. (2014) · Bone · doi:10.1016/j.bone.2014.06.037 · Cited by 23
Osteoporosis: Treat-to-Target
Lewiecki, E. M. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0350-7 · Cited by 23
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday
Xu, L., ADAMS-HUET, B. A., POINDEXTER, J. R., & Maalouf, N. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3447-9 · Cited by 22
Assessing the Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: An Updated Systematic Review and Network Meta‐Analyses
Bastounis, A., Langley, T. E., Davis, S., Paskins, Z., Gittoes, N. J. L., Leonardi‐Bee, J., & Sahota, O. (2022) · JBMR Plus · doi:10.1002/jbm4.10620 · Cited by 21
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions
Ruža, I., Mirfakhraee, S., ORWOLL, E. S., & Gruntmanis, U. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13485829 · Cited by 23
Medication use to manage comorbidities for people with dementia: a systematic review
Page, A. T., Etherton‐Beer, C., Seubert, L., Clark, V., Hill, X., King, S., & Clifford, R. M. (2018) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1403 · Cited by 23
Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
Tai, T., Chen, H., Shih, C., Huang, C., McCloskey, E. V., Lee, J. K., Yeap, S. S., Cheung, C., Charatcharoenwitthaya, N., Jaisamrarn, U., et al. (2024) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2024.02.001 · Cited by 22
Self-citation
Epidemiology, radiology and histology of atypical femoral fractures
Schilcher, J. (2013) · Acta Orthopaedica · doi:10.3109/17453674.2013.850008 · Cited by 21
Special Considerations to Improve Clinical Outcomes in Patients with Osteoporosis Undergoing Spine Surgery
Fiani, B., Newhouse, A. C., Sarhadi, K. J., Arshad, M. A., Soula, M., & Cathel, A. (2021) · The International Journal of Spine Surgery · doi:10.14444/8050 · Cited by 22
Changes in bone mineral density and bone turnover in patients on ‘drug holiday’ following bisphosphonate therapy: real‐life clinic setting
Roberts, J. D., Castro, C. H. D. M., Moore, A. E. B., Fogelman, I., & Hampson, G. (2015) · Clinical Endocrinology · doi:10.1111/cen.13012 · Cited by 23
Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost
Chodick, G., Moser, S. S., & Goldshtein, I. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2016.1171145 · Cited by 22
Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men
Bolland, M. J., Horne, A. M., Briggs, S. E., Thomas, M. G., Reid, I. R., Gamble, G. D., & Grey, A. B. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3712 · Cited by 21
Self-citation
Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?
Bauer, D. C., & Abrahamsen, B. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00660-4 · Cited by 21
Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women
Izano, M. A., Lo, J. C.-M., Adams, A. L., Ettinger, B. B., Ott, S. M., Chandra, M., Hui, R. L., Niu, F., Li, B. H., & Neugebauer, R. S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25190 · Cited by 25
Real-world effectiveness of osteoporosis treatments in Germany
O’Kelly, J., Bartsch, R., Kossack, N., Borchert, J., Pignot, M., & Hadji, P. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01156-z · Cited by 22
Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis—a retrospective-prospective study from southern India
Sooragonda, B. G., Cherian, K. E., Jebasingh, F., Dasgupta, R., Asha, H. S., Kapoor, N., Thomas, N., & Paul, T. V. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0630-1 · Cited by 20
Medical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Choi, H. S., Park, S. Y., Kim, Y. M., Kim, S. H., Kim, K. M., & Chung, Y. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.003 · Cited by 20
Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study
Cipriani, C., Pepe, J., Clementelli, C., Manai, R., Colangelo, L., Fassino, V., Nieddu, L., & Minisola, S. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13332 · Cited by 20
A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Dedov, I. I., Drapkina, O. M., Fadeev, V. V., Golounina, O. O., Lesnyak, O. M., Mamedova, E., Mel'nichenko, G. A., Petraikin, A. V., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06667-6 · Cited by 24
Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics
Bagán, L., Jimenez, Y., Leopoldo, M., Murillo‐Cortes, J., & Sebastián, J. V. B. (2017) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.22133 · Cited by 19
An Essential Warning
Leder, B. Z. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3359 · Cited by 20
II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica
Orjuela, A. M., Rosero, O., Rueda-Plata, P. N., Escobar, F. S., Chalem, M., Reyes, M., Román-Gonzaléz, A., Lozano, A. T., Talero, A. P., Beltz, C. R., et al. (2018) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2018.02.006 · Cited by 29
Actualisation 2012 des recommandations françaises du traitement médicamenteux de l’ostéoporose post-ménopausique
Briot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R. D., Fardellone, P., Féron, J.-M., et al. (2012) · Revue du Rhumatisme · doi:10.1016/j.rhum.2012.02.006 · Cited by 18
Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: A retrospective cohort study
Seki, K., Kaneko, T., Kamimoto, A., Wada, M., Takeuchi, Y., Furuchi, M., & Iinuma, T. (2022) · Journal of Dental Sciences · doi:10.1016/j.jds.2022.03.014 · Cited by 20
Target Values and Daytime Variation of Bone Turnover Markers in Monitoring Osteoporosis Treatment After Fractures
Borgen, T. T., Solberg, L. B., Lauritzen, T., Apalset, E. M., Bjørnerem, Å., & Eriksen, E. F. (2022) · JBMR Plus · doi:10.1002/jbm4.10633 · Cited by 18
Long-Term Follow-up of patients on Drug Holiday from Bisphosphonates: Real-World Setting
Chiha, M., Myers, L., Ball, C. A., Sinacore, J. M., & Camacho, P. M. (2013) · Endocrine Practice · doi:10.4158/ep12425.or · Cited by 18
Going on a Drug Holiday?
Bonnick, S. L. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.07.006 · Cited by 18
Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae
Krause, M., Soltau, Zimmermann, E., Hahn, M. P., Kornet, J. J., Hapfelmeier, A., Breer, S., Morlock, M. M., Wulff, B., Püschel, K., et al. (2014) · European Cells and Materials · doi:10.22203/ecm.v028a12 · Cited by 18
Zoledronic acid for prevention and treatment of osteoporosis
Recknor, C. P. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.562201 · Cited by 18
Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review
Liu, S., Tan, Y., Huang, W., Luo, H., Pan, B., & Wu, S. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152304 · Cited by 17
Increased risk of stroke among hip fracture patients: a nationwide cohort study
Tsai, C., Lin, C., Hsu, H.-C., & Chung, W. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2919-7 · Cited by 17
Pharmacotherapy of Paget's disease of bone
Reid, I. R. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.662486 · Cited by 17
Self-citation
Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia
Huang, S., Lin, H. V., Zhu, X.-F., Chen, X., Fan, L., & Liu, C. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0014 · Cited by 17
Atypical Femur Fractures Associated With Diphosphonate Use
Balach, T., Baldwin, P. C., & Intravia, J. M. (2015) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-14-00024 · Cited by 17
Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height
Robinson, M., Trejo, P., Palomo, T., Glorieux, F. H., & Rauch, F. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3833 · Cited by 17
Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy—a long-term radiological follow-up
Png, M. A., Mohan, P. C., Koh, J. S. B., Howe, C. Y., & Howe, T. S. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05067-7 · Cited by 17

Authors: Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., Leung, P. C., Man, Z., Martinez, R. L. M., Tan, M., Ruzycky, M. E., Su, G., & Eastell, R.
Affiliations: University of California, San Francisco (US)
University of Auckland (NZ)
KU Leuven (BE)
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
University of Pittsburgh (US)
Helen Hayes Hospital (US)
California Pacific Medical Center (US)
University Hospital of Bern (CH)
Semmelweis University (HU)
Chinese University of Hong Kong (HK)
Centro Médico TIEMPO, Buenos Aires, Argentina
University of Sheffield (GB)
Corresponding author: Black, Dennis M
ORCID: Black, Dennis M
Reid, Ian R
Bucci-Rechtweg, Christina
Cauley, Jane A
Cosman, Felicia
Cummings, Steven R
Hue, Trisha F
Lippuner, Kurt
Lakatos, Peter
Leung, Ping Chung
Tan, Monique
Eastell, Richard
Venue: Journal of Bone and Mineral Research
Publisher: Oxford University Press (OUP)
Published: 2011-12-08
Volume: 27
Issue: 2
Pages: 243-254
ISSN: 0884-0431 (ISSN-L)
1523-4681
DOI: 10.1002/jbmr.1494
PMC: PMC3427916
OpenAlex: W2106406207
Cited by: 700
References: 40
Citations by year: 2026: 18 · 2025: 37 · 2024: 29 · 2023: 45 · 2022: 40 · 2021: 58 · 2020: 53 · 2019: 49 · 2018: 48 · 2017: 54 · 2016: 61 · 2015: 62 · 2014: 50 · 2013: 49 · 2012: 35
FWCI: 49.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: Journal of Bone and Mineral Research (publishedVersion)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: National Institutes of Health (UL1TR000005)
University of California, San Francisco
Novartis Pharma
National Center for Research Resources (UL1RR024153)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: zoledronic acid, osteoporosis, postmenopausal women, long-term treatment, bone mineral density, femoral neck, vertebral fractures, fracture risk, bone turnover markers, serum creatinine, atrial fibrillation, stroke, hypertension, bisphosphonates, adverse events
MeSH terms: Zoledronic Acid, Aged, Diphosphonates, Female, Follow-Up Studies, Humans, Imidazoles, Osteoporosis, Peptide Fragments, Procollagen, Time Factors, Biomarkers, Bone Density, Incidence, Bone Remodeling, Treatment Outcome, Bone Density Conservation Agents, Osteoporotic Fractures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks